| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| Albanes 1986 | Named trial: ATBC pilot<br>RCT<br>Jadad Score: 5<br>Population: Smokers<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 8 Months | n Entered: N/D<br>n Analyzed: N/D | Excluded from statistical analysis because of insufficient statistics. This pilot study for the ATBC lung cancer prevention trial showed the feasibility of conducting the larger trial. Death and development of cancers were reported as explanations for dropouts, but these data were not broken down by type of intervention. |
| | | 2 | Beta-carotene<br>20 mg orally for 8 Months | n Entered: N/D<br>n Analyzed: N/D | |
| | | 3 | Vitamin E<br>50 mg orally for 8 Months | n Entered: N/D<br>n Analyzed: N/D | |
| | | 4 | Beta-carotene<br>20 mg orally for 8 Months<br>Vitamin E<br>50 mg orally for 8 Months | n Entered: N/D<br>n Analyzed: N/D | |
| Albanes 1996 | Named trial: ATBC<br>RCT<br>Jadad Score: 3<br>Population: Smokers<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6.1 Years | n Entered: 7287<br>n Analyzed: 7287 | Statistical pooling performed:<br>Death: relative risk at 6.1 years (average follow-up)<br>New tumor: relative risk at 6.1 years (average follow-up) |
| | | 2 | Beta-carotene<br>20 mg orally for 6.1 Years | n Entered: 7282<br>n Analyzed: 7282 | |
| | | 3 | Vitamin E<br>50 mg orally for 6.1 Years | n Entered: 7286<br>n Analyzed: 7286 | |
| | | 4 | Beta-carotene<br>20 mg orally for 6.1 Years<br>Vitamin E<br>50 mg orally for 6.1 Years | n Entered: 7278<br>n Analyzed: 7278 | |
| Albanes 2000 | Named trial: ATBC<br>RCT<br>Jadad Score: 3<br>Population: Smokers<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6.1 Years | n Entered: 7287<br>n Analyzed: 7287 | Statistical pooling performed:<br>Death: relative risk at 6.1 years (average follow-up)<br>New tumor: relative risk at 6.1 years (average follow-up) |
| | | 2 | Beta-carotene<br>20 mg orally for 6.1 Years | n Entered: 7282<br>n Analyzed: 7282 | |
| | | 3 | Vitamin E<br>50 mg orally for 6.1 Years | n Entered: 7286<br>n Analyzed: 7286 | |
| | | 4 | Vitamin E<br>50 mg orally for 6.1 Years<br>Beta-carotene<br>20 mg orally for 6.1 Years | n Entered: 7278<br>n Analyzed: 7278 | |

N/D = not described

**Antioxidants For Cancer Prevention/Treatment**

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| ATBC Prevention Study Group 1994 | Named trial: ATBC<br>RCT<br>Jadad Score: 3<br>Population: Smokers<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6.1 Years | n Entered: 7287<br>n Analyzed: 7287 | Statistical pooling performed:<br>Death: relative risk at 6.1 years (average follow-up)<br>New tumor: relative risk at 6.1 years (average follow-up) |
| | | 2 | Vitamin E<br>50 mg orally for 6.1 Years | n Entered: 7286<br>n Analyzed: 7286 | |
| | | 3 | Beta-carotene<br>20 mg orally for 6.1 Years | n Entered: 7282<br>n Analyzed: 7282 | |
| | | 4 | Vitamin E<br>50 mg orally for 6.1 Years<br>Beta-carotene<br>20 mg orally for 6.1 Years | n Entered: 7278<br>n Analyzed: 7278 | |

N/D = not described

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| Blot 1993 | Named trial: Linxian<br>(General Population Trial)<br>RCT<br><br>Jadad Score: 2<br><br>Population: N/D<br><br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 5.25 Years | n Entered: N/D<br>n Analyzed: 3679 | Statistical pooling performed:<br>Death: relative risk at 5.25 years follow-up |
| | | 2 | Niacin<br>40 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered: N/D<br>n Analyzed: 3701 | |
| | | 3 | Vitamin C<br>120 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered: N/D<br>n Analyzed: 3694 | |
| | | 4 | Vitamin C<br>120 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered: N/D<br>n Analyzed: 3703 | |
| | | 5 | Vitamin E<br>30 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered: N/D<br>n Analyzed: 3691 | |
| | | 6 | Vitamin C<br>120 mg orally for 5.25 Years<br>Vitamin E<br>30 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered: N/D<br>n Analyzed: 3699 | |
| | | 7 | Vitamin C<br>120 mg orally for 5.25 Years<br>Vitamin E<br>30 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered: N/D<br>n Analyzed: 3705 | |

N/D = not described

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| | | 8 | Vitamin E<br>30 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered: N/D<br>n Analyzed: 3712 | |
| Bussey 1982 | Named trial: No<br>RCT<br>Jadad Score: 4<br>Population: N/D<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 2 Years | n Entered: 22<br>n Analyzed: 17 | Excluded from polyps meta-analysis because of insufficient statistics. Individuals all had polyposis coli. Those in Arm 2 exhibited reduction of colonic polyp area ($p < 0.03$) at 9 months and had a nonsignificant trend towards reduction in number and area of rectal polyps. |
| | | 2 | Vitamin C<br>3 gm orally for 2 Years | n Entered: 25<br>n Analyzed: 19 | |
| Cahill 1993 | Named trial: No<br>RCT<br>Jadad Score: 2<br>Population: N/D<br>Comorbidities: N/D | 1 | Control or Usual care<br>No dosage data reported | n Entered: 10<br>n Analyzed: 10 | Excluded from statistical analysis because there were no outcomes of interest. Reduction in cell proliferation in colonic crypts in patients with adenomatous polyps was found with vitamin C in all crypt components and with beta-carotene at the base only. There was no significant effect on cell proliferation from vitamin E supplementation. |
| | | 2 | Beta-carotene<br>9 mg orally for 1 Month | n Entered: 10<br>n Analyzed: 10 | |
| | | 3 | Vitamin E<br>160 mg orally for 1 Month | n Entered: 10<br>n Analyzed: 10 | |
| | | 4 | Vitamin C<br>750 mg orally for 1 Month | n Entered: 10<br>n Analyzed: 10 | |
| Correa 2000 | Named trial: No<br>RCT<br>Jadad Score: 5<br>Population: N/D<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6 Years | n Entered: 117<br>n Analyzed: 76 | Excluded from statistical analysis because there were no outcomes of interest. Within this study of metaplasia, there was no statistically significant difference among treatment groups in progression or regression of dysplasia. |
| | | 2 | H. pylori treatment<br>N/D dose orally for 6 Years | n Entered: 120<br>n Analyzed: 79 | |
| | | 3 | Beta-carotene<br>30 mg orally for 6 Years | n Entered: 117<br>n Analyzed: 65 | |
| | | 4 | Vitamin C<br>2 gm orally for 6 Years | n Entered: 130<br>n Analyzed: 91 | |

N/D = not described

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| | | 5 | Beta-carotene<br>30 mg orally for 6 Years<br>H. pylori treatment<br>N/D dose orally for 6 Years | n Entered: 126<br>n Analyzed: 88 | |
| | | 6 | H. pylori treatment<br>N/D dose orally for 6 Years<br>Vitamin C<br>2 gm orally for 6 Years | n Entered: 111<br>n Analyzed: 72 | |
| | | 7 | Beta-carotene<br>30 mg orally for 6 Years<br>Vitamin C<br>2 gm orally for 6 Years | n Entered: 121<br>n Analyzed: 79 | |
| | | 8 | H. pylori treatment<br>N/D dose orally for 6 Years<br>Beta-carotene<br>30 mg orally for 6 Years<br>Vitamin C<br>2 gm orally for 6 Years | n Entered: 134<br>n Analyzed: 81 | |
| Creagan 1979(Mar) | Named trial: No<br>RCT<br>Jadad Score: 4<br>Population: N/D<br>Comorbidities: Cancer | 1 | Placebo<br>Placebo taken until death | n Entered: N/D<br>n Analyzed: N/D | Excluded from statistical analysis because of insufficient statistics. No difference was found between the treatment groups in terms of symptoms, functional status, appetite, weight, or survival among subjects with advanced cancer. |
| | | 2 | Vitamin C<br>10 gm orally until death | n Entered: N/D<br>n Analyzed: N/D | |

N/D = not described

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| Creagan 1979(Sep) | Named trial: No<br>RCT<br>Jadad Score: 4<br>Population: N/D<br>Comorbidities: N/D | 1 | Placebo<br>No dosage data reported | n Entered: 75<br>n Analyzed: 63 | Excluded from death analysis because of insufficient statistics: Study only reported survival curve. All subjects had various forms of advanced cancer. No significant difference was shown between the two groups in terms of changes in symptoms, performance status, appetite, weight or survival. |
| | | 2 | Vitamin C<br>10 gm orally, duration N/D | n Entered: 75<br>n Analyzed: 60 | |
| Dawsey 1994 | Named trial: Linxian (Dysplasia trial)<br>RCT<br>Jadad Score: 2<br>Population: N/D<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6 Years | n Entered: N/D<br>n Analyzed: 368 | Statistical pooling performed:<br>New tumor: relative risk at 30 months and 6 years follow-up |
| | | 2 | Vitamin C<br>180 mg orally for 6 Years<br>Vitamin E<br>60 IU orally for 6 Years<br>Multi-vitamin<br>Multi-vitamin orally for 6 Years<br>Beta-carotene<br>15 mg orally for 6 Years<br>Vitamin A<br>10000 IU orally for 6 Years<br>Selenium<br>50 µg orally for 6 Years | n Entered: N/D<br>n Analyzed: 400 | |
| DeCosse 1989 | Named trial: No<br>RCT<br>Jadad Score: 5<br>Population: N/D<br>Comorbidities: N/D | 1 | Fiber<br>2.2 gm orally for 4 years<br>Vitamin C<br>4030 mg orally for 4 Years<br>Vitamin A<br>2000 IU orally for 4 Years<br>Placebo<br>Placebo for 4 years | n Entered: 22<br>n Analyzed: 21 | |

N/D = not described

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| | | 2 | Vitamin C<br>4030 mg orally for 4 Years<br>Vitamin E<br>400 mg orally for 4 Years<br>Fiber<br>2.2 gm orally for 4 Years<br>Vitamin A<br>2000 IU orally for 4 Years | n Entered: 16<br>n Analyzed: 14 | |
| | | 3 | Vitamin C<br>4030 mg orally for 4 Years<br>Vitamin E<br>400 mg orally for 4 Years<br>Fiber<br>22.5 gm orally for 4 Years<br>Vitamin A<br>2000 IU orally for 4 Years | n Entered: 20<br>n Analyzed: 19 | |
| Gogos 1998 | Named trial: No<br><br>RCT<br><br>Jadad Score: 1<br><br>Population: N/D<br><br>Comorbidities: N/D | 1 | Placebo<br>No dosage data reported<br>Vitamin C<br>4030 mg orally for 4 Years | n Entered: 30<br>n Analyzed: 30<br>n Entered: 16<br>n Analyzed: 14 | Excluded from death analysis because of insufficient statistics: Study only reported survival curve. All subjects had various types of solid tumors. Those receiving the active intervention had prolonged survival ($p < 0.025$) compared with placebo. This group also exhibited higher TNF production ($p < 0.05$) in malnourished subjects. |
| | | 2 | Vitamin E<br>200 mg orally, duration N/D<br>Fish oil<br>18 gm orally, duration N/D | n Entered: 30<br>n Analyzed: 30 | |

N/D = not described

**Antioxidants For Cancer Prevention/Treatment**

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| Greenberg 1994 | Named trial: No<br>RCT<br>Jadad Score: 4<br>Population: N/D<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 4 Years | n Entered: N/D<br>n Analyzed: 187 | Statistical pooling performed:<br>Polyps: meta-analysis at 1 year follow-up |
| | | 2 | Beta-carotene<br>25 mg orally for 4 Years | n Entered: N/D<br>n Analyzed: 184 | |
| | | 3 | Vitamin C<br>1 gm orally for 4 Years<br>Vitamin E<br>400 mg orally for 4 Years | n Entered: N/D<br>n Analyzed: 205 | |
| | | 4 | Vitamin C<br>1 gm orally for 4 Years<br>Vitamin E<br>400 mg orally for 4 Years<br>Beta-carotene<br>25 mg orally for 4 Years | n Entered: N/D<br>n Analyzed: 175 | |
| Heinonen 1998 | Named trial: ATBC<br>RCT<br>Jadad Score: 3<br>Population: Smokers<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6.1 Years-+ | n Entered: 7287<br>n Analyzed: 7287 | Statistical pooling performed:<br>Death: relative risk at 6.1 years (average follow-up)<br>New tumor: relative risk at 6.1 years (average follow-up) |
| | | 2 | Beta-carotene<br>20 mg orally for 6.1 Years | n Entered: 7282<br>n Analyzed: 7282 | |
| | | 3 | Vitamin E<br>50 mg orally for 6.1 Years | n Entered: 7286<br>n Analyzed: 7286 | |
| | | 4 | Vitamin E<br>50 mg orally for 6.1 Years<br>Beta-carotene<br>20 mg orally for 6.1 Years | n Entered: 7278<br>n Analyzed: 7278 | |

N/D = not described

**Antioxidants For Cancer Prevention/Treatment**

| First Author Year | Trial name<br>Study Design<br>Quality<br>Population<br>Comorbidities | Arm | Interventions<br>Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| Hofstad 1998 | Named trial: No<br><br>RCT<br><br>Jadad Score: 3<br><br>Population: N/D<br><br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 3 Years | n Entered: 51<br>n Analyzed: 51 | Statistical pooling performed:<br>Polyps: meta-analysis at 3 years follow-up |
| | | 2 | Vitamin E<br>75 mg orally for 3 Years<br>Vitamin C<br>150 mg orally for 3 Years<br>Beta-carotene<br>15 mg orally for 3 Years<br>Ca<br>1.6 gm orally for 3 Years<br>Selenium<br>101 µg orally for 3 Years | n Entered: 42<br>n Analyzed: 42 | |
| Lamm 1994 | Named trial: No<br><br>RCT<br><br>Jadad Score: 4<br><br>Population: N/D<br><br>Comorbidities: N/D | 1 | Multi-vitamin<br>Multi-vitamin orally for 40 Months<br>Vitamin E<br>30 IU orally for 40 Months<br>Vitamin C<br>60 mg orally for 40 Months<br>Vitamin A<br>5000 IU orally for 40 Months | n Entered: 30<br>n Analyzed: 30 | Statistical pooling performed:<br>Death: relative risk at 45 months follow-up |
| | | 2 | Vitamin E<br>430 IU orally for 49 Months<br>Vitamin C<br>2060 mg orally for 49 Months<br>Vitamin A<br>45000 IU orally for 49 Months<br>Multi-vitamin<br>Multi-vitamin orally for 49 Months | n Entered: 35<br>n Analyzed: 35 | |

N/D = not described

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| Li, Bing 1993 Study A | Named trial: Linxian (Dysplasia Trial)<br>RCT<br><br>Jadad Score: 2<br><br>Population: N/D<br><br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6 Years | n Entered: 1661<br>n Analyzed: N/D | Excluded from statistical analysis because of duplicate data, same data as another report. This paper describes the design and methods of the Linxian trials. Deaths and development of cancers were reported for the total population, but these data were not broken down by type of intervention. |
| | | 2 | Vitamin C<br>180 mg orally for 6 Years<br>Vitamin E<br>60 IU orally for 6 Years<br>Multi-vitamin<br>Multi-vitamin orally for 6 Years<br>Beta-carotene<br>15 mg orally for 6 Years<br>Vitamin A<br>10000 IU orally for 6 Years<br>Selenium<br>50 µg orally for 6 Years | n Entered: 1657<br>n Analyzed: N/D | |
| Li, Bing 1993 Study B | Named trial: Linxian (General Population Trial)<br>RCT<br><br>Jadad Score: 2<br><br>Population: N/D<br><br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6 Years | n Entered: 1661<br>n Analyzed: N/D | Excluded from statistical analysis because of insufficient statistics. This is a pilot study for the Linxian General Population trial. |
| | | 2 | Vitamin C<br>180 mg orally for 6 Years<br>Vitamin E<br>60 IU orally for 6 Years<br>Multi-vitamin<br>Multi-vitamin orally for 6 Years<br>Beta-carotene<br>15 mg orally for 6 Years<br>Vitamin A<br>10000 IU orally for 6 Years<br>Selenium<br>50 µg orally for 6 Years | n Entered: 1657<br>n Analyzed: N/D | |

N/D = not described

**Antioxidants For Cancer Prevention/Treatment**

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| Li, Jun-Yao 1993 | Named trial: Linxian (Dysplasia Trial)<br>RCT<br>Jadad Score: 2<br>Population: N/D<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6 Years | n Entered: 1661<br>n Analyzed: 1661 | Statistical pooling performed:<br>Death: relative risk at 6 years follow-up<br>New tumor: relative risk at 6 years follow-up |
| | | 2 | Vitamin C<br>180 mg orally for 6 Years<br>Vitamin E<br>60 IU orally, duration N/D<br>Multi-vitamin<br>Multi-vitamin orally, duration N/D<br>Beta-carotene<br>15 mg orally, duration N/D<br>Vitamin A<br>10000 IU orally, duration N/D<br>Selenium<br>50 µg orally, duration N/D | n Entered: 1657<br>n Analyzed: 1657 | |
| Liede 1998 | Named trial: ATBC<br>RCT<br>Jadad Score: 3<br>Population: Smokers<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6 Years | n Entered: 119<br>n Analyzed: N/D | Excluded from statistical analysis because there were no outcomes of interest. No significant difference was found among any of the four groups in the incidence of any oral mocosal lesions evaluated including leukoplakia, keratoses, hyperplasia and mucosal dysplasia. |
| | | 2 | Vitamin E<br>50 mg orally for 6 Years | n Entered: 95<br>n Analyzed: N/D | |
| | | 3 | Vitamin E<br>50 mg orally for 6 Years<br>Beta-carotene<br>20 mg orally for 6 Years | n Entered: 96<br>n Analyzed: N/D | |
| | | 4 | Beta-carotene<br>20 mg orally for 6 Years | n Entered: 99<br>n Analyzed: N/D | |

N/D = not described

**Antioxidants For Cancer Prevention/Treatment**

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| Mackerras 1999 | Named trial: No<br>RCT<br>Jadad Score: 4<br>Population: Female<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 2 Years | n Entered: N/D<br>n Analyzed: 35 | Excluded from statistical analysis because there were no outcomes of interest. There was no significant difference found among the groups in terms of regression or progression of cervical intraepithelial neoplasia (CIN) I. |
| | | 2 | Beta-carotene<br>30 mg orally for 2 Years | n Entered: N/D<br>n Analyzed: 36 | |
| | | 3 | Vitamin C<br>518 mg orally for 2 Years | n Entered: N/D<br>n Analyzed: 35 | |
| | | 4 | Vitamin C<br>518 mg orally for 2 Years<br>Beta-carotene<br>30 mg orally for 2 Years | n Entered: N/D<br>n Analyzed: 35 | |
| Malila 1999 | Named trial: ATBC<br>RCT<br>Jadad Score: 3<br>Population: Smokers<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6.3 Years | n Entered: 3887<br>n Analyzed: N/D | Excluded from polyps analysis because of insufficient statistics: Statistics too heterogeneous to pool. Vitamin E increased the risk for colorectal adenoma (RR 95% CI 1.19-2.32) among participants. There was no interaction between vitamin E and beta-carotene on risk for adenoma. |
| | | 2 | Beta-carotene<br>20 mg orally for 6.3 Years | n Entered: 3883<br>n Analyzed: N/D | |
| | | 3 | Beta-carotene<br>20 mg orally for 6.3 Years<br>Vitamin E<br>50 mg orally for 6.3 Years | n Entered: 3878<br>n Analyzed: N/D | |
| | | 4 | Vitamin E<br>50 mg orally for 6.3 Years | n Entered: 3890<br>n Analyzed: N/D | |
| McKeown-Eyssen 1988 | Named trial: No<br>RCT<br>Jadad Score: 3<br>Population: N/D<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 2 Years | n Entered: 89<br>n Analyzed: 67 | Statistical pooling performed:<br>Polyps: meta-analysis at 2 years follow-up |
| | | 2 | Vitamin C<br>400 mg orally for 2 Years<br>Vitamin E<br>400 mg orally for 2 Years | n Entered: 96<br>n Analyzed: 70 | |

N/D = not described

**Antioxidants For Cancer Prevention/Treatment**

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| Moertel 1985 | Named trial: No<br>RCT<br>Jadad Score: 3<br>Population: N/D<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 3.6 Months | n Entered: 49<br>n Analyzed: 49 | Excluded from death analysis because of insufficient statistics: study only reported total death. All subjects had advanced colorectal cancer. No significant difference was shown between the groups in terms of disease progression or survival. |
| | | 2 | Vitamin C<br>10 gm orally for 2.5 Months | n Entered: 51<br>n Analyzed: 51 | |
| MRC/BHF 2002 | Named trial: Other<br>RCT<br>Jadad Score: 5<br>Population: Unspecified<br>Comorbidities: DM | 1 | Placebo<br>Placebo for 5 Years | n Entered: 10267<br>n Analyzed: 10228 | Statistical pooling performed |
| | | 2 | Vitamin E<br>600 mg orally for 5 Years<br>Vitamin C<br>250 mg orally for 5 Years<br>Beta-carotene<br>20 mg orally for 5 Years | n Entered: 10269<br>n Analyzed: 10241 | |
| Nutrition Review 1985 | Named trial: No<br>RCT<br>Jadad Score: 2<br>Population: N/D<br>Comorbidities: Cancer | 1 | Placebo<br>No dosage data reported | n Entered: 49<br>n Analyzed: 49 | Statistical pooling performed:<br>Death: relative risk at 1 year follow-up |
| | | 2 | Vitamin C<br>10 gm orally, duration N/D | n Entered: 51<br>n Analyzed: 51 | |

N/D = not described

**Antioxidants For Cancer Prevention/Treatment**

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| Poulter 1984 | Named trial: No<br>CCT<br>Jadad Score: 0<br>Population: Female<br>Comorbidities: N/D | 1 | Control or Usual care<br>Control or Usual care for 5 Years | n Entered: 25<br>n Analyzed: 24 | Statistical pooling performed:<br>Death: relative risk at 5 years follow-up |
| | | 2 | Vitamin C<br>3 gm orally for 5 Years | n Entered: 27<br>n Analyzed: 27 | |
| Rautalahti 1999 | Named trial: ATBC<br>RCT<br>Jadad Score: 3<br>Population: Smokers<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6.1 Years | n Entered: 7287<br>n Analyzed: 7287 | Statistical pooling performed:<br>Death: relative risk at 6.1 years (average follow-up)<br>New tumor: relative risk at 6.1 years (average follow-up) |
| | | 2 | Vitamin E<br>50 mg orally for 6.1 Years | n Entered: 7286<br>n Analyzed: 7286 | |
| | | 3 | Beta-carotene<br>20 mg orally for 6.1 Years | n Entered: 7282<br>n Analyzed: 7282 | |
| | | 4 | Vitamin E<br>50 mg orally for 6.1 Years<br>Beta-carotene<br>20 mg orally for 6.1 Years | n Entered: 7278<br>n Analyzed: 7278 | |
| Roncucci, Di Donato 1993 | Named trial: No<br>RCT<br>Jadad Score: 2<br>Population: N/D<br>Comorbidities: N/D | 1 | Control or Usual care<br>No dosage data reported | n Entered: N/D<br>n Analyzed: 78 | Statistical pooling performed:<br>Polyps: meta-analysis at 12 months follow-up |
| | | 2 | Lactulose<br>20 gm orally for 18 Months | n Entered: N/D<br>n Analyzed: 61 | |
| | | 3 | Vitamin C<br>1 gm orally for 18 Months<br>Vitamin E<br>70 mg orally for 18 Months<br>Vitamin A<br>30000 IU orally for 18 Months | n Entered: N/D<br>n Analyzed: 70 | |

N/D = not described

**Antioxidants For Cancer Prevention/Treatment**

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| Roncucci 1993 | Named trial: No<br>RCT<br>Jadad Score: 2<br>Population: N/D<br>Comorbidities: N/D | 1 | Control or Usual care<br>Control/Usual care for 18 Months | n Entered: 78<br>n Analyzed: 78 | Excluded from polyps meta-analysis because study reported data duplicated in another included study (Roncucci, Di Donato 1993) |
| | | 2 | Lactulose<br>20 gm orally for 18 Months | n Entered: 61<br>n Analyzed: 61 | |
| | | 3 | Vitamin E<br>70 mg orally for 18 Months<br>Vitamin C<br>1 gm orally for 18 Months<br>Vitamin A<br>30000 IU orally for 18 Months | n Entered: 70<br>n Analyzed: 70 | |
| Schroder 2000 | Named trial: No<br>RCT<br>Jadad Score: 2<br>Population: N/D<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6 Weeks | n Entered: 37<br>n Analyzed: N/D | Excluded from statistical analysis because there were no outcomes of interest. The slope of the rise of PSA and PSA doubling times decreased among those receiving antioxidant supplementation (29.5 vs. 60 weeks doubling time, p<0.05) in prostate cancer patients with rising PSA values post prostatectomy or radiotherapy. |
| | | 2 | Vitamin E<br>N/D dose orally for 6 Weeks<br>Selenium<br>N/D dose orally for 6 Weeks<br>Multi-vitamin<br>Multi-vitamin orally for 6 Weeks | n Entered: 37<br>n Analyzed: N/D | |
| Taylor 1994 Study A | Named trial: Linxian (Dysplasia Trial)<br>RCT<br>Jadad Score: 2<br>Population: N/D<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6 Years | n Entered: 1661<br>n Analyzed: 1661 | Excluded from new tumor analysis because of insufficient statistics. Subjects in the dysplasia trial all had esophageal dysplasia without malignancy. This report describes the methods of the dysplasia trial but reports no results from it. |
| | | 2 | Vitamin C<br>180 mg orally for 6 Years<br>Vitamin E<br>60 IU orally for 6 Years<br>Multi-vitamin<br>Multi-vitamin orally for 6 Years<br>Beta-carotene<br>15 mg orally for 6 Years<br>Vitamin A<br>10000 IU orally for 6 Years<br>Selenium<br>50 µg orally for 6 Years | n Entered: 1657<br>n Analyzed: 1657 | |

N/D = not described

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | | Summary of Results |
|---|---|---|---|---|---|---|
| Taylor 1994 Study B | Named trial: Linxian (General Population Trial) RCT<br><br>Jadad Score: 2<br><br>Population: N/D<br><br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 5.25 Years | n Entered:<br>n Analyzed: | N/D<br>3679 | Statistical pooling performed:<br>New tumor: relative risk at 5.25 years follow-up. |
| | | 2 | Niacin<br>40 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered:<br>n Analyzed: | N/D<br>3701 | |
| | | 3 | Vitamin C<br>120 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered:<br>n Analyzed: | N/D<br>3694 | |
| | | 4 | Vitamin C<br>120 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered:<br>n Analyzed: | N/D<br>3703 | |
| | | 5 | Vitamin E<br>30 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered:<br>n Analyzed: | N/D<br>3691 | |
| | | 6 | Vitamin C<br>120 mg orally for 5.25 Years<br>Vitamin E<br>30 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered:<br>n Analyzed: | N/D<br>3699 | |
| | | 7 | Vitamin C<br>120 mg orally for 5.25 Years<br>Vitamin E<br>30 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered:<br>n Analyzed: | N/D<br>3705 | |

N/D = not described

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| | | 8 | Vitamin E<br>30 mg orally for 5.25 Years<br>Multi-vitamin<br>Multi-vitamin orally for 5.25 Years | n Entered: N/D<br>n Analyzed: 3712 | |
| Varis 1998 | Named trial: ATBC<br>RCT<br>Jadad Score: 3<br>Population: Smokers<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 5.1 Years | n Entered: 333<br>n Analyzed: 333 | Statistical pooling performed:<br>New tumor: relative risk at 6.1 years (average follow-up) |
| | | 2 | Beta-carotene<br>20 mg orally for 5.1 Years | n Entered: 329<br>n Analyzed: 329 | |
| | | 3 | Vitamin E<br>50 mg orally for 5.1 Years | n Entered: 321<br>n Analyzed: 321 | |
| | | 4 | Beta-carotene<br>20 mg orally for 5.1 Years<br>Vitamin E<br>50 mg orally for 5.1 Years | n Entered: 361<br>n Analyzed: 361 | |
| Virtamo 2000 | Named trial: ATBC<br>RCT<br>Jadad Score: 3<br>Population: Smokers<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 6.1 Years | n Entered: 7287<br>n Analyzed: 7287 | Statistical pooling performed:<br>Death: relative risk at 6.1 years (average follow-up)<br>New tumor: relative risk at 6.1 years (average follow-up) |
| | | 2 | Vitamin E<br>50 mg orally for 6.1 Years | n Entered: 7286<br>n Analyzed: 7286 | |
| | | 3 | Beta-carotene<br>20 mg orally for 6.1 Years | n Entered: 7282<br>n Analyzed: 7282 | |
| | | 4 | Vitamin E<br>50 mg orally for 6.1 Years<br>Beta-carotene<br>20 mg orally for 6.1 Years | n Entered: 7278<br>n Analyzed: 7278 | |

N/D = not described

**Antioxidants For Cancer Prevention/Treatment**

| First Author Year | Trial name Study Design Quality Population Comorbidities | Arm | Interventions Dosage Data | Sample Size | Summary of Results |
|---|---|---|---|---|---|
| Zaridze 1993 | Named trial: No<br>RCT<br>Jadad Score: 4<br>Population: N/D<br>Comorbidities: N/D | 1 | Placebo<br>Placebo for 20 Months | n Entered: N/D<br>n Analyzed: N/D | Excluded from statistical analysis because there were no outcomes of interest. Among men with oral leukoplakia and/or chronic esophagitis, those in arm 3 exhibited a decreased OR for oral leukoplakia after 6 months ((5% CI 0.39-0.98) as compared with placebo. There was no significant difference in risk of progression of chronic esophagitis after 20 months. |
| | | 2 | Riboflavin<br>11.4 mg orally for 20 Months | n Entered: N/D<br>n Analyzed: N/D | |
| | | 3 | Vitamin E<br>11.4 mg orally for 20 Months<br>Vitamin A<br>14285 IU orally for 20 Months<br>Beta-carotene<br>40 mg orally for 20 Months | n Entered: N/D<br>n Analyzed: N/D | |
| | | 4 | Riboflavin<br>11.4 mg orally for 20 Months<br>Vitamin E<br>11.4 mg orally for 20 Months<br>Vitamin A<br>14285 IU orally for 20 Months<br>Beta-carotene<br>40 mg orally for 20 Months | n Entered: N/D<br>n Analyzed: N/D | |
| Zullo 2000 | Named trial: No<br>RCT<br>Jadad Score: 2<br>Population: N/D<br>Comorbidities: N/D | 1 | Control or Usual care<br>Control or Usual care for 6 Months | n Entered: 33<br>n Analyzed: 29 | Statistical pooling performed:<br>Excluded from statistical analysis because there were no outcomes of interest. |
| | | 2 | Vitamin C<br>500 mg orally for 6 Months | n Entered: 32<br>n Analyzed: 29 | |

N/D = not described